Effect of insufficient insulin treatment in streptozotocin-induced diabetes mellitus

Pancreas

Volumn 34, Issue 3, 2007, Pages 354-358

  Ozmen, Ozlem ^a   Topsakal, Senay ^b   Sahinduran, Sima ^a   Ozcelik, Mahiye ^a  

^a MEHMET AKIF ERSOY UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Immunohistochemistry; Insufficient insulin treatment; Insulin dependent diabetes mellitus; Pathology; Streptozotocin

Indexed keywords

INSULIN LISPRO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; KETONURIA; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; PANCREAS; PROINSULIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34247157756     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31802f082f     Document Type: Article

References (20)

1. Eisenbarth GS, Connelly J, Soeldner JS. The "natural" history of type I diabetes. Diabetes Metab Rev. 1987;3:873-891.
2. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol. 1992;51:285-322.
3. Capen CC. Endocrine system. In: Carlton WW, McGavin MD, eds. Thomson's Special Pathology. St Louis, MO: Mosby Year Book, Inc; 1995:276-278.
4. Unger RH, Foster DW. Diabetes mellitus. In: Wilson JD, Foster DW, Kronenberg HM, et al, eds. Williams Textbook of Endocrinology. Philadelphia, PA: WB Saunders Co; 1998:973-1059.
5. Jones TC, Hunt RD, King NW. Veterinary Pathology. Baltimore, MD: Williams & Wilkins Co; 1997.
6. Hoenig M. Diabetes Mellitus in Dogs and Cats. III. National Small Animal Veterinary Medicine Congress With International Guest Speakers, Bursa, Turkey. 2006:49-55.
7. Jerrold HZ. Biostatistical Analysis. 3rd rev ed. Englewood Cliffs, NJ: Prentice-Hall; 1996.
8. Boyd ME, Albright EB, Foster DW, et al. In vitro reversal of the fasting state of liver metabolism in the rat. J Clin Invest. 1981;68:142-152.
9. Thulesen J, Orskov C, Holst JJ, et al. Short-term insulin treatment prevents the diabetogenic action of streptozotocin in rats. Endocrinology. 1997;138(1):62-68.
10. Tancrede G, Roussea-Migneron S, Nadeau A. Long-term changes in the diabetogenic state induced by different doses of streptozotocin in rats. Br J Exp Pathol. 1983;64:117-123.
11. Simon OR, West ME. Unstable diabetic state produced by a small dose of streptozotocin in rats. West Indian Med J. 1992;41:146-149.
12. Iwase M, Nunoi K, Wakisaka M, et al. Spontaneous recovery from non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin treatment in spontaneously hypertensive rats. Metabolism. 1991;40:10-14.
13. Ar Rajab A, Ahren B. Long-term diabetogenic effect of streptozotocin in rats. Pancreas. 1993;1:50-57.
14. Maiti R, Das UK, Ghosh D. Attenuation of hyperglycemia in streptozotocin-induced diabetic rats by aqueous extract of seed of Tamarindus indica. Biol Pharm Bull. 2005;28(7):1172-1176.
15. Nyholm B, Orskov L, Hove K, et al. The amylin analogue pramlintide decreases post-prandial plasma glucose and glucagon in IDDM. Diabetes. 1997;56(suppl 1):33A, 128.
16. Schmitz O, Nyholm B, Orskov L, et al. Effect of amylin and the amylin agonist pramlintide on glucose metabolism. Diabet Med. 1997;14(suppl):S19-S23.
17. Kolterman OG. Amylin and glycaemic regulation: a possible role for the humanamylin analogue pramlintide. Diabet Med. 1997;14(suppl):S35-S38.
18. Feudner CA. Disease in motion: diabetes history and the new paradigm of transmuted disease. Perspect Biol Med. 1996;39:158-170.
19. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in diabetes. Diabetes Care. 2004;27(suppl 1):S94-S102.
20. Reichel A, Rietzsch H, Kohler HJ, et al. Cessation of insulin infusion at night-time during CSII therapy: comparison of regular human insulin and insulin lispro. Exp Clin Endocrinol Diabetes. 1998;106:168-172.